U.S. Healthtech Stock News

NasdaqCM:SAFX
NasdaqCM:SAFXOil and Gas

XCF Global (SAFX) Q4 Loss Renews Concerns Over Earnings Quality Despite Profitable TTM EPS

XCF Global (SAFX) closed FY 2025 with Q4 revenue of US$4.7 million and a basic EPS loss of US$0.09, alongside trailing twelve month EPS of US$0.52 on revenue of US$20.8 million that reflects the move into profitability over the past year. Over recent quarters the company has seen revenue shift from US$0 in Q1 2025 to US$6.6 million in Q2, US$9.6 million in Q3, then US$4.7 million in Q4. Quarterly EPS moved from a loss of US$0.05 in Q1 to a gain of US$0.83 in Q2 before returning to losses in...
NasdaqGS:PLAY
NasdaqGS:PLAYHospitality

Dave And Buster’s Entertainment (PLAY) EPS Loss Deepens Bear Concerns On Profitability Narratives

Dave & Buster's Entertainment (PLAY) has just wrapped up FY 2026 with fourth quarter revenue of US$529.6 million and a basic EPS loss of US$1.15, as net income excluding extra items came in at a loss of US$39.8 million. Over the past year, quarterly revenue has moved between US$448.2 million and US$567.7 million, while basic EPS has ranged from a profit of US$0.63 in the first quarter to losses of around US$1.15 to US$1.22 in the back half of the year. This sets up a complex picture for...
NYSE:FCX
NYSE:FCXMetals and Mining

Freeport-McMoRan (FCX) Is Up 7.2% After Launching Performance-Based Dividend And Announcing Board Change

Freeport-McMoRan Inc. recently declared a US$0.15 per share cash dividend on its common stock, combining a US$0.075 base payout and a US$0.075 variable component under its performance-based framework, while Board member Robert W. Dudley confirmed he will not stand for re-election at the 2026 annual meeting. This mix of a performance-linked dividend and an orderly Board transition comes as analysts project very large near-term earnings growth and maintain a strongly positive consensus view on...
NasdaqGS:RUSH.A
NasdaqGS:RUSH.ATrade Distributors

A Look At Rush Enterprises (RUSH.A) Valuation After The Appointment Of New Chief Operating Officer

Leadership change and what it could mean for Rush Enterprises stock Rush Enterprises (RUSH.A) has appointed long time executive Jody Pollard as Chief Operating Officer, replacing Jason Wilder. This shift places internal operational experience at the center of investor attention. See our latest analysis for Rush Enterprises. The leadership change comes as Rush Enterprises trades at US$66.02, with a 30 day share price return of an 8.76% decline, a 90 day share price return of 22.40% and a 5...
NYSE:FOR
NYSE:FORReal Estate

A Look At Forestar Group’s Valuation As Backlog And Analyst Target Diverge From Share Price

Why Forestar Group is on investors’ radar today Forestar Group (FOR) has drawn fresh attention after a period where the share price showed mixed short term moves, including a 1 day gain alongside weaker returns over the month. For readers tracking real estate related names, the stock’s recent share performance and financial profile, including revenue of US$1,685.0 million and net income of US$166.8 million, raise questions about how the market is currently viewing its valuation. See our...
NYSE:LW
NYSE:LWFood

Lamb Weston (LW) Q3 Earnings Show 6.1% Net Margin Progress Testing Bullish Narratives

Lamb Weston Holdings (LW) has put fresh numbers on the board for Q3 2026, with quarterly revenue of about US$1.6b and basic EPS of US$0.45, while the latest trailing twelve month figures show revenue of roughly US$6.5b and EPS of US$2.80. Over recent periods the company has seen quarterly revenue move between about US$1.52b and US$1.68b and basic EPS range from a loss of US$0.25 per share to US$1.03 per share, alongside trailing twelve month EPS running between roughly US$2.08 and US$2.80...
NYSE:GS
NYSE:GSCapital Markets

How Basel III Capital Relief And AI Ambitions At Goldman Sachs (GS) Has Changed Its Investment Story

In recent weeks, Goldman Sachs Group has issued a broad range of new fixed-income securities across currencies and maturities while benefiting from Basel III revisions that reduce capital requirements for large banks, supporting its capacity to lend, underwrite and return capital. Analysts now see a stronger business outlook driven by expectations for increased mergers and acquisitions activity and deeper use of artificial intelligence across Goldman’s operations, which together could...
NasdaqGS:RBCA.A
NasdaqGS:RBCA.ABanks

Is It Time To Reassess Republic Bancorp (RBCA.A) After Strong Multi Year Share Price Gains

If you are wondering whether Republic Bancorp's current share price gives you good value, the starting point is understanding how that price lines up against a few different valuation yardsticks. The stock last closed at US$70.96, with returns of 3.2% over 7 days, 1.7% over 30 days, 4.3% year to date, 13.4% over 1 year, 89.0% over 3 years and 82.2% over 5 years, which gives useful context before comparing the price to value. Recent attention on Republic Bancorp has centered on its role in...
NasdaqGS:ILMN
NasdaqGS:ILMNLife Sciences

Is It Time To Reassess Illumina (ILMN) After Its Recent Share Price Volatility?

For readers wondering whether Illumina at around US$126.63 is priced for opportunity or already reflects the current story, this article walks through what the share price might be implying about value. The stock has had a mixed run, with a 0.3% return over 7 days and a 4.7% decline over 30 days, set against a 54.7% gain over the past year and longer term declines of 43.6% over 3 years and 67.5% over 5 years. These moves have come as Illumina remains in focus for investors, following ongoing...
NasdaqGS:PODD
NasdaqGS:PODDMedical Equipment

Assessing Insulet (PODD) Valuation After Omnipod 5 Device Correction And Maintained Outlook

Insulet (PODD) recently disclosed a voluntary device correction for certain Omnipod 5 lots after 18 serious adverse events, including hospitalizations and diabetic ketoacidosis, while affirming its existing outlook and excluding remediation costs from non GAAP results. See our latest analysis for Insulet. The voluntary device correction and recent executive appointments come at a time of softer share performance, with a 30 day share price return of 15.65% and a 1 year total shareholder return...
NYSE:RCL
NYSE:RCLHospitality

How Royal Caribbean’s New Tri‑Branded Credit Cards At Royal Caribbean Cruises (RCL) Has Changed Its Investment Story

Royal Caribbean Group and Bank of America recently launched the Royal ONE and Royal ONE Plus tri-branded Visa Signature credit cards, allowing guests to earn and redeem rewards across Royal Caribbean, Celebrity Cruises, and Silversea with tiered point multipliers and travel perks. The new cards deepen Royal Caribbean Group’s loyalty ecosystem by tying everyday spending to cruise savings and onboard credits, reinforcing its focus on higher-value, repeat guests. Next, we’ll explore how this...
NasdaqGS:SOFI
NasdaqGS:SOFIConsumer Finance

Musk’s SpaceX IPO Clarification Keeps SoFi Access Story In Focus

Elon Musk publicly denied rumors that SoFi Technologies would be excluded from the upcoming SpaceX IPO. Musk confirmed that retail focused platforms like SoFi remain part of the plan for SpaceX share access. The clarification follows media speculation that raised questions about SoFi’s role in high profile IPO allocations. For investors watching SoFi Technologies (NasdaqGS:SOFI), Musk’s comments directly touch on one of the areas that sets the platform apart: access to sought after...
NYSEAM:BMNR
NYSEAM:BMNRSoftware

If You Believe In Cryptocurrency And Blockchain Stocks Then These Three Pivots Could Define The Next Cycle

Crypto and blockchain stocks sit at the intersection of technology, finance, and changing market plumbing, which can be appealing when geopolitical tensions, energy prices, and bond yields keep shifting. With manufacturing data mixed across regions and input costs under pressure, many investors are looking beyond traditional sectors to themes tied to digital infrastructure and alternative transaction systems. Our Top Cryptocurrency and Blockchain Stocks screener filters this broad universe...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

A Look At Ligand Pharmaceuticals (LGND) Valuation After Strong Multi Year Shareholder Returns

Ligand Pharmaceuticals (LGND) has been drawing attention after recent share performance data highlighted mixed short term returns alongside stronger longer term outcomes, prompting investors to reassess how its current pricing lines up with fundamentals. See our latest analysis for Ligand Pharmaceuticals. At a share price of $199.62, Ligand Pharmaceuticals has seen short term share price pressure, with a 7 day return of 2.41% and a 30 day return of 1.45%. Longer horizons show stronger...
NasdaqCM:JFB
NasdaqCM:JFBConstruction

JFB Construction Holdings (JFB) Net Loss Deepens Challenging Bullish Narratives

JFB Construction Holdings (JFB) has just posted another tough set of numbers for FY 2025, with Q3 revenue of US$5.0 million and a basic EPS loss of US$0.05, set against a trailing 12 month revenue decline of 20.4% and no net profit over the period. The company has seen quarterly revenue move from US$7.1 million in Q4 2024 to US$5.9 million in Q1 2025, US$3.7 million in Q2 2025, and US$5.0 million in Q3 2025. EPS shifted from a modest profit of US$0.02 per share in Q4 2024 to small gains in Q1...
NasdaqGS:ACGL
NasdaqGS:ACGLInsurance

A Look At Arch Capital Group (ACGL) Valuation After Recent Share Price Softness

Arch Capital Group overview and recent share performance Arch Capital Group (ACGL) has attracted attention after recent price moves, with the stock down about 5.5% over the past month and roughly flat over the past 3 months. At a last close of US$95.49 and a market cap of about US$34.1b, the Bermuda based insurance and reinsurance group offers exposure across insurance, reinsurance and mortgage segments, each contributing meaningful revenue. See our latest analysis for Arch Capital...
NYSE:IMAX
NYSE:IMAXEntertainment

Assessing IMAX (IMAX) Valuation After Recent Share Price Volatility

IMAX stock performance snapshot IMAX (IMAX) is back on radar for some investors after recent share price moves, with the stock up about 1.7% over the past day but showing an 8.0% decline over the past month. That short term pullback sits alongside a 4.5% gain over the past 3 months and a 7.3% return year to date. This underlines how volatile shorter windows can look when you zoom in. See our latest analysis for IMAX. At a share price of $38.64, IMAX has paired a recent 8.0% one month share...
NYSE:RACE
NYSE:RACEAuto

Ferrari (NYSE:RACE) Valuation Check After Mixed Short Term And Long Term Share Returns

What Ferrari (RACE) investors can glean from recent performance Ferrari (RACE) has drawn attention after a mixed run in the stock, with a 1 day gain of 1.18% and a 6.29% move over the past week, in contrast with weaker returns over the past month and past 3 months. See our latest analysis for Ferrari. At a share price of $342.43, Ferrari’s recent rebound, including the 7 day share price return of 6.29%, contrasts with a softer 30 day and year to date share price trend. The 1 year total...
NYSE:NREF
NYSE:NREFMortgage REITs

NexPoint Real Estate Finance (NREF) Revenue Jump Tests Bearish Decline Narrative After FY 2025 Results

NexPoint Real Estate Finance (NREF) just wrapped up FY 2025 with Q4 total revenue of US$30.0 million and basic EPS of US$0.67. Trailing twelve month revenue came in at US$157.3 million and EPS at US$4.28. Over the past year, the company has seen revenue move from US$73.1 million to US$157.3 million on a trailing basis, with EPS shifting from US$1.02 to US$4.28. This context allows investors to weigh these results against expectations. With margins running well ahead of the prior year, the...
NYSE:KD
NYSE:KDIT

Is It Time To Reassess Kyndryl Holdings (KD) After A 61% One-Year Share Price Slide

Considering whether Kyndryl Holdings is starting to look like value after a tough run, or if the current price still does not fully reflect the risks. The stock last closed at US$12.85, with returns of 1.6% over 7 days and 0.2% over 30 days, but a much softer picture year to date with a 49.6% decline and a 61.2% decline over 1 year. Recent coverage has focused on Kyndryl Holdings as a standalone IT services player following its separation from IBM. This has highlighted the challenge of...
NYSE:TPC
NYSE:TPCConstruction

Assessing Tutor Perini (TPC) Valuation After Strong Recent Share Price Momentum

Tutor Perini (TPC) has recently drawn investor attention after its shares closed at $78.71. The company reported annual revenue of US$5.54b and net income of US$80.44m from its diversified construction operations. See our latest analysis for Tutor Perini. The recent 1-month share price return of 6.99% and 90-day share price return of 17.44% sit against a very large 1-year total shareholder return, suggesting that momentum has been building over both shorter and longer horizons. If Tutor...
NYSE:MGM
NYSE:MGMHospitality

IAC’s Larger MGM Stake Puts Governance And Capital Allocation In Focus

IAC/InterActiveCorp, led by Barry Diller, has increased its stake in MGM Resorts International to more than 23%. This move makes IAC the largest shareholder of MGM Resorts International, reinforcing its role in the company’s ownership structure. The development highlights fresh attention on NYSE:MGM and how large shareholders may influence future decisions. MGM Resorts International, trading under NYSE:MGM, last closed at $36.78. The stock shows a 19.6% return over the past year, while...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

Does Shoals’ BESS Webinar And Options Spike Reshape Its Competitive Narrative For SHLS?

Shoals Technologies Group recently took part in a Barclays-hosted virtual webinar on battery energy storage systems, where its president and BESS product lead discussed the company’s products, market paths, and competitive positioning for investors and other interested participants. At the same time, Shoals has seen heightened options market activity and implied volatility, suggesting traders are closely watching potential catalysts around its BESS expansion and broader outlook. We’ll now...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart Data - What's Changed

Viridian Therapeutics recently reported positive topline results from its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease, showing significant improvements in eye bulging and double vision with subcutaneous dosing and a generally manageable safety profile. Yet the data immediately sparked debate over how elegrobart stacks up against existing thyroid eye disease therapies, putting the focus on differentiation rather than simple success or failure of the trial. Next, we’ll...